NAMPT and acute myeloid leukemia: Their previous clinical trial data with Venetoclax-Azacytidine combination further suggested that the LSCs in de-novo and relapsed/refractory AML are metabolically very distinct and provide a window of opportunity for such poor prognosis patients with NAMPT small molecule inhibitors (APO866 and KPT-9274) along with chemotherapy or Venetoclax based combinations.